Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
NCT07675070
·
clinicaltrials.gov ↗
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Brain Tumor
Grade III Glioma
Grade IV Glioma
Interventions
DRUG:
temozolomide
Sponsor
NanoAlvand